Zacks Investment Research upgraded shares of Fibrocell Science (NASDAQ:FCSC) from a sell rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Several other research firms have also weighed in on FCSC. ValuEngine upgraded shares of Fibrocell Science from a sell rating to a hold rating in a research note on Saturday, June 2nd. HC Wainwright restated a buy rating and set a $22.00 price objective on shares of Fibrocell Science in a research note on Tuesday, June 5th.

Shares of FCSC stock opened at $2.01 on Wednesday. Fibrocell Science has a 1 year low of $1.75 and a 1 year high of $18.90.

Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.50). analysts forecast that Fibrocell Science will post -3.31 EPS for the current year.

A hedge fund recently raised its stake in Fibrocell Science stock. Point72 Asset Management L.P. lifted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 100.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 400,000 shares of the company’s stock after purchasing an additional 200,000 shares during the period. Point72 Asset Management L.P. owned 1.41% of Fibrocell Science worth $236,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Featured Story: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.